Treatment options for patients with aMCD
| . | No. of patients . | Percentage . |
|---|---|---|
| CHOP and CHOP-like | 18 | 41.9 |
| R-CHOP/R-CHOP-like/R plus glucocorticoids | 10 | 23.3 |
| TCP/TCD/TD | 5 | 11.6 |
| BCD/BD | 2 | 4.7 |
| Lenalidomide-based therapy | 2 | 4.7 |
| Tocilizumab plus glucocorticoids | 1 | 2.3 |
| Glucocorticoids monotherapy | 2 | 4.7 |
| Other combination therapy | 3 | 7.0 |
| . | No. of patients . | Percentage . |
|---|---|---|
| CHOP and CHOP-like | 18 | 41.9 |
| R-CHOP/R-CHOP-like/R plus glucocorticoids | 10 | 23.3 |
| TCP/TCD/TD | 5 | 11.6 |
| BCD/BD | 2 | 4.7 |
| Lenalidomide-based therapy | 2 | 4.7 |
| Tocilizumab plus glucocorticoids | 1 | 2.3 |
| Glucocorticoids monotherapy | 2 | 4.7 |
| Other combination therapy | 3 | 7.0 |
BCD, bortezomib, cyclophosphamide, and dexamethasone; BD, bortezomib and dexamethasone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; TCD, thalidomide, cyclophosphamide, and dexamethasone; TCP, thalidomide, cyclophosphamide, and prednisone; TD, thalidomide and dexamethasone.